The CVP,Strategy of Edwards Lifesciences (NYSE: EW) is Selling Shares

By Carrie Williams

Today, the CVP,Strategy of Edwards Lifesciences (NYSE: EW), Donald Bobo, sold shares of EW for $478.2K.

Following Donald Bobo’s last EW Sell transaction on August 08, 2017, the stock climbed by 11.2%. In addition to Donald Bobo, one other EW executive reported Sell trades in the last month.

Based on Edwards Lifesciences’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $889 million and GAAP net loss of $2.8 million. In comparison, last year the company earned revenue of $768 million and had a net profit of $159 million. The company has a one-year high of $138.48 and a one-year low of $89.20. EW’s market cap is $26.85B and the company has a P/E ratio of 47.17.

Based on 11 analyst ratings, the analyst consensus is Strong Buy with an average price target of $150.09, reflecting a -15.2% downside. Five different firms, including Citigroup and J.P. Morgan, currently also have a Sell rating on the stock.

The insider sentiment on Edwards Lifesciences has been negative according to 75 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Edwards Lifesciences Corp. engages in the design, development, manufacture, and markets products to treat stage cardiovascular disease. It operates through the following geographical segments: United States, Europe, Japan, and Rest of the World.